HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) CME Activity Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Nabi, H. A. Articles by Zubeldia, J. M. Search for Related Content PubMed PubMed Citation Articles by Nabi, H. A. Articles by Zubeldia, J. M.

Clinical Applications of ¹⁸F-FDG in Oncology

Department of Nuclear Medicine, State University of New York at Buffalo, Buffalo, New York

PET has emerged as a powerful diagnostic tool for the evaluation of cancer patients. Currently, most of these studies are performed with the glucose analog ¹⁸F-FDG, which has been shown to accumulate avidly in most tumors. ¹⁸F-FDG PET is now routinely used in the diagnosis, staging, and posttherapy evaluation of oncologic patients. After reading this paper, the reader should understand the physiologic basis of using ¹⁸F-FDG in patients with different tumors, describe the role of this radiopharmaceutical in the management of oncologic patients, and identify those malignancies for which ¹⁸F-FDG has proved to be effective in diagnosis and follow-up.

Key Words: ¹⁸F-FDG PET; tumor

This article has been cited by other articles:

				B. E. Lee, J. Redwine, C. Foster, E. Abella, T. Lown, D. Lau, and D. Follette Mediastinoscopy might not be necessary in patients with non-small cell lung cancer with mediastinal lymph nodes having a maximum standardized uptake value of less than 5.3 J. Thorac. Cardiovasc. Surg., March 1, 2008; 135(3): 615 - 619. [Abstract] [Full Text] [PDF]

				N. Al-Sarraf, R. Aziz, K. Gately, J. Lucey, L. Wilson, E. McGovern, and V. Young Pattern and predictors of occult mediastinal lymph node involvement in non-small cell lung cancer patients with negative mediastinal uptake on positron emission tomography Eur. J. Cardiothorac. Surg., January 1, 2008; 33(1): 104 - 109. [Abstract] [Full Text] [PDF]

				R. J. Cerfolio and A. S. Bryant When is it Best to Repeat a 2-Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography/Computed Tomography Scan on Patients with Non-Small Cell Lung Cancer Who Have Received Neoadjuvant Chemoradiotherapy? Ann. Thorac. Surg., October 1, 2007; 84(4): 1092 - 1097. [Abstract] [Full Text] [PDF]

				S. Chong, T. S. Kim, B.-T. Kim, E. Y. Cho, and J. Kim Pulmonary Artery Sarcoma Mimicking Pulmonary Thromboembolism: Integrated FDG PET/CT Am. J. Roentgenol., June 1, 2007; 188(6): 1691 - 1693. [Full Text] [PDF]

				R. J. Cerfolio and A. S. Bryant Ratio of the Maximum Standardized Uptake Value on FDG-PET of the Mediastinal (N2) Lymph Nodes to the Primary Tumor May Be a Universal Predictor of Nodal Malignancy in Patients With Nonsmall-Cell Lung Cancer Ann. Thorac. Surg., May 1, 2007; 83(5): 1826 - 1830. [Abstract] [Full Text] [PDF]

				Y. Miao, K. Benwell, and T. P. Quinn 99mTc- and 111In-Labeled {alpha}-Melanocyte-Stimulating Hormone Peptides as Imaging Probes for Primary and Pulmonary Metastatic Melanoma Detection J. Nucl. Med., January 1, 2007; 48(1): 73 - 80. [Abstract] [Full Text] [PDF]

				A. S. Bryant and R. J. Cerfolio The clinical stage of non-small cell lung cancer as assessed by means of fluorodeoxyglucose-positron emission tomographic/computed tomographic scanning is less accurate in cigarette smokers J. Thorac. Cardiovasc. Surg., December 1, 2006; 132(6): 1363 - 1368. [Abstract] [Full Text] [PDF]

				R. J. Cerfolio, A. S. Bryant, and M. A. Eloubeidi Routine Mediastinoscopy and Esophageal Ultrasound Fine-Needle Aspiration in Patients With Non-small Cell Lung Cancer Who Are Clinically N2 Negative: A Prospective Study Chest, December 1, 2006; 130(6): 1791 - 1795. [Abstract] [Full Text] [PDF]

				A. S. Bryant and R. J. Cerfolio The maximum standardized uptake values on integrated FDG-PET/CT is useful in differentiating benign from malignant pulmonary nodules. Ann. Thorac. Surg., September 1, 2006; 82(3): 1016 - 1020. [Abstract] [Full Text] [PDF]

				R. J. Cerfolio and A. S. Bryant Maximum Standardized Uptake Values on Positron Emission Tomography of Esophageal Cancer Predicts Stage, Tumor Biology, and Survival Ann. Thorac. Surg., August 1, 2006; 82(2): 391 - 395. [Abstract] [Full Text] [PDF]

				A. S. Bryant, R. J. Cerfolio, K. M. Klemm, and B. Ojha Maximum Standard Uptake Value of Mediastinal Lymph Nodes on Integrated FDG-PET-CT Predicts Pathology in Patients with Non-Small Cell Lung Cancer Ann. Thorac. Surg., August 1, 2006; 82(2): 417 - 423. [Abstract] [Full Text] [PDF]

				R. J. Cerfolio, A. S. Bryant, and B. Ojha Restaging patients with N2 (stage IIIa) non-small cell lung cancer after neoadjuvant chemoradiotherapy: A prospective study J. Thorac. Cardiovasc. Surg., June 1, 2006; 131(6): 1229 - 1235. [Abstract] [Full Text] [PDF]

				R. J. Cerfolio, A. S. Bryant, B. Ojha, and M. Eloubeidi Improving the Inaccuracies of Clinical Staging of Patients with NSCLC: A Prospective Trial Ann. Thorac. Surg., October 1, 2005; 80(4): 1207 - 1214. [Abstract] [Full Text] [PDF]

				R. J. Cerfolio, A. S. Bryant, B. Ohja, and A. A. Bartolucci The maximum standardized uptake values on positron emission tomography of a non-small cell lung cancer predict stage, recurrence, and survival J. Thorac. Cardiovasc. Surg., July 1, 2005; 130(1): 151 - 159. [Abstract] [Full Text] [PDF]

				M. R. Acker and S. C. Burrell Utility of 18F-FDG PET in Evaluating Cancers of Lung J. Nucl. Med. Technol., June 1, 2005; 33(2): 69 - 74. [Abstract] [Full Text] [PDF]

				R. J. Cerfolio, A. S. Bryant, B. Ohja, A. A. Bartolucci, and M. A. Eloubeidi The accuracy of endoscopic ultrasonography with fine-needle aspiration, integrated positron emission tomography with computed tomography, and computed tomography in restaging patients with esophageal cancer after neoadjuvant chemoradiotherapy J. Thorac. Cardiovasc. Surg., June 1, 2005; 129(6): 1232 - 1241. [Abstract] [Full Text] [PDF]

				R. J. Cerfolio, A. S. Bryant, T. S. Winokur, B. Ohja, and A. A. Bartolucci Repeat FDG-PET After Neoadjuvant Therapy is a Predictor of Pathologic Response in Patients With Non-Small Cell Lung Cancer Ann. Thorac. Surg., December 1, 2004; 78(6): 1903 - 1909. [Abstract] [Full Text] [PDF]

				D. C.P. Cobben, P. L. Jager, P. H. Elsinga, B. Maas, A. J.H. Suurmeijer, and H. J. Hoekstra 3'-18F-Fluoro-3'-Deoxy-L-Thymidine: A New Tracer for Staging Metastatic Melanoma? J. Nucl. Med., December 1, 2003; 44(12): 1927 - 1932. [Abstract] [Full Text] [PDF]

				Z.-X. He, R.-F. Shi, Y.-J. Wu, Y.-Q. Tian, X.-J. Liu, S.-W. Wang, R. Shen, X.-W. Qin, R.-L. Gao, J. Narula, et al. Direct Imaging of Exercise-Induced Myocardial Ischemia With Fluorine-18-Labeled Deoxyglucose and Tc-99m-Sestamibi in Coronary Artery Disease Circulation, September 9, 2003; 108(10): 1208 - 1213. [Abstract] [Full Text] [PDF]

				A. Goel, S. P. Mathupala, and P. L. Pedersen Glucose Metabolism in Cancer. EVIDENCE THAT DEMETHYLATION EVENTS PLAY A ROLE IN ACTIVATING TYPE II HEXOKINASE GENE EXPRESSION J. Biol. Chem., April 18, 2003; 278(17): 15333 - 15340. [Abstract] [Full Text] [PDF]